Related Experiment Videos
Multicenter trial of naloxone in Alzheimer's disease
V W Henderson1, E Roberts, C Wimer
1Department of Neurology, University of Southern California School of Medicine, Los Angeles 90033.
Annals of Neurology
|April 1, 1989
Abstract:
In a double-blind, placebo-controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1-mg or 10-mg doses; 15 patients at 1 center were similarly unimproved after receiving 30 mg naloxone (single blind). Findings fail to support claims that naloxone monotherapy ameliorates cognitive impairments of Alzheimer's disease.